score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	Clinical evidence		Clinical evidence	Somatic Variant	NRAS	Missense	p.Q61K	0.5537	475.0	0.0	0.0		Investigate Actionability - High	Selumetinib	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956							Investigate Actionability - High	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	313.0	0.623	1.0	NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat47	MEL-IPI_Pat47-Tumor-SM-4DK28	MEL-IPI_Pat47-Normal-SM-53U5U
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.P25L	0.6142	127.0	0.0	0.0																			0	440.0	0.5795	1.0	FGFR1 p.P25L (Missense)		MEL-IPI_Pat47	MEL-IPI_Pat47-Tumor-SM-4DK28	MEL-IPI_Pat47-Normal-SM-53U5U
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E596V	0.3889	468.0	0.0	0.0																			0	0.0	0.0	0.0	FGFR2 p.E596V (Missense)		MEL-IPI_Pat47	MEL-IPI_Pat47-Tumor-SM-4DK28	MEL-IPI_Pat47-Normal-SM-53U5U
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat47		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.558																							0				COSMIC Signature 7 (56%)		MEL-IPI_Pat47		
